tiprankstipranks
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
US Market

TransCode Therapeutics (RNAZ) Financial Statements

205 Followers

TransCode Therapeutics Financial Overview

TransCode Therapeutics's market cap is currently ―. The company's EPS TTM is $-205.921; its P/E ratio is >-0.01; TransCode Therapeutics is scheduled to report earnings on August 12, 2024, and the estimated EPS forecast is $-0.58. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -3.34M$ -5.30M$ -4.34M$ -4.90M$ -5.53M
EBITDA$ -3.20M$ -5.16M-$ -4.80M$ -5.50M
Net Income Common Stockholders$ -3.33M$ -5.30M$ -4.34M$ -4.82M$ -5.13M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 4.90M$ 7.50M$ 3.60M$ 1.60M$ 5.00M
Total Assets$ 7.29M$ 10.23M$ 5.88M$ 5.59M$ 7.59M
Total Debt$ 339.41K$ 594.69K$ 663.29K$ 768.23K$ 0.00
Net Debt$ -4.56M$ -6.91M$ -2.94M$ -831.77K$ -5.00M
Total Liabilities$ 2.71M$ 5.79M$ 3.79M$ 5.83M$ 4.35M
Stockholders Equity$ 4.58M$ 4.44M$ 2.09M$ -236.79K$ 3.24M
Cash Flow-
Free Cash Flow$ -3.90M--$ -4.53M$ -4.13M
Operating Cash Flow$ -3.90M$ -3.50M$ -4.40M$ -4.51M$ -4.10M
Investing Cash Flow$ -3.84K$ -4.61K$ -18.11K$ -12.90K$ -28.21K
Financing Cash Flow$ 6.09M$ 7.39M$ 6.36M$ 1.18M$ 225.82K
Currency in USD

TransCode Therapeutics Earnings and Revenue History

TransCode Therapeutics Debt to Assets

TransCode Therapeutics Cash Flow

TransCode Therapeutics Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis